HIV-associated progressive multifocal leukoencephalopathy. Current perspectives by Iannetta, M. et al.
AUTH
OR
PROO
F 
COPY
 
Not fo
r 
public
ation
© 2016 Iannetta et al. This work is published by Dove Medical Press Limited, and licensed under a Creative Commons Attribution License.  
The full terms of the License are available at http://creativecommons.org/licenses/by/4.0/. The license permits unrestricted use, distribution, 
and reproduction in any medium, provided the original author and source are credited.
© 2016 Iannetta et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms. 
php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work 
you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For 
permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
Neurobehavioral HIV Medicine 2016:7 43–52
Neurobehavioral HIV Medicine Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
43
R E V I E W
open access to scientific and medical research
Open Access Full Text Article
http://dx.doi.org/10.2147/NBHIV.S107941
HIV-associated progressive multifocal 
leukoencephalopathy: current perspectives
Marco Iannetta 
Maria Antonella Zingaropoli 
Alessandra D’Abramo 
Alessandra Oliva 
Claudio Maria Mastroianni 
Vincenzo Vullo 
Maria Rosa Ciardi 
Department of Public Health 
and Infectious Diseases, Sapienza 
University, Rome, Italy 
Abstract: Progressive multifocal leukoencephalopathy (PML) is a demyelinating disease of the 
central nervous system, caused by the polyomavirus JC and occurring almost exclusively in the 
context of severe immune depression. AIDS represents the most common predisposing condi-
tion for PML development. Antiretroviral treatment has reduced PML incidence in HIV-infected 
subjects, but the disease remains a severe and life-threatening complication of AIDS, considering 
thus far the lack of an effective anti-JC virus (JCV) direct-acting antiviral drug. In the last decade, 
the use of monoclonal antibodies for treating immune-based diseases evidenced new predisposing 
conditions for PML development, promoting a renewed interest in PML pathogenesis. In this 
article, we review the current knowledge on JCV epidemiology and AIDS-associated PML inci-
dence, JCV viral cycle, pathogenesis, and the interplay with HIV infection. We give an updated 
overview of diagnostic and prognostic tools available for PML diagnosis and describe past and 
current therapeutic approaches, including new strategies for PML cure.
Keywords: PML, JCV, NeuroAIDS, IRIS, diagnosis, therapy
Introduction
Progressive multifocal leukoencephalopathy (PML) is a debilitating and demyelinating 
disease of the central nervous system (CNS) which occurs almost exclusively in the 
context of severe impairment of the immune system, like AIDS, immunomodulatory 
therapy with monoclonal antibodies (mAbs), immune suppression after solid organ 
or hematopoietic stem cell transplants, and cancer.1–3
PML is caused by a polyomavirus first identified from brain lesions of a patient 
with PML, and named JC virus (JCV) from the patient’s initials (John Cunningham).4-6 
Although JCV infects the worldwide population at a very high rate, PML remains 
a rare disorder. The introduction of combination antiretroviral therapies (cART) 
improved recovery of HIV-treated patients from severe immunosuppression, thus 
reducing the PML risk.7
In this review, we will summarize the epidemiology, the biology, and clinical pre-
sentation of HIV-related PML. We will also show what is known about the delicate 
interplay between JCV and the host immune system during HIV infection and discuss 
future perspectives.
PML history and epidemiology
The first case of PML was described in 1958 by Astrom et al,4 who showed the presence 
of inclusion bodies in the nuclei of damaged oligodendrocytes with electron microscopy, 
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 suggesting a possible viral cause. It was only in 1971 that 
Padgett et al characterized the etiologic agent of PML, by cultur-
ing JCV from PML brain lesions in human fetal spongioblasts.6 
Before the AIDS pandemic, PML has been a rare and 
obscure disorder affecting old patients with predisposing 
conditions.4 From 1958 to 1984, Brooks and Walker identi-
fied 230 cases of PML, 40 of which were pathologically 
and virologically confirmed and 69 only pathologically 
confirmed.8 The most common PML-associated predispos-
ing illnesses were lymphoproliferative diseases (62.2%), 
myeloproliferative diseases (6.5%), carcinoma (2.2%), and 
granulomatous and inflammatory diseases (7.4%). In 5.6% of 
PML patients, no immunosuppressive predisposing disorders 
were identified.9
After the spread of HIV in the early 1980s, the PML inci-
dence has increased 50-fold compared to previous years10 and 
occurred in 1%–10% of AIDS cases, with AIDS accounting 
for 55%–85% of PML cases.11 With the introduction of cART, 
the PML incidence in HIV-infected patients has decreased 
because of the restoration of anti-JCV T-cell immunity.7 For 
this reason, the history of HIV-associated PML is character-
ized by two distinct phases: before and after cART introduc-
tion. According to the data from the EuroSIDA cohort, in 
the pre-cART era, PML incidence in HIV-infected subjects 
was 2–10 cases for 1,000 person-years and dropped down 
to one case for 1,000 person-years in the post-cART era.12,13 
Furthermore, cART improved 1-year survival of HIV-infected 
patients with PML, ranging from 9% in the pre-cART era7 
to  30% in the post-cART era. Today the 1-year survival rate 
is 50% or higher in patients under effective antiretroviral 
treatment, compared to 5% or lower in patients not receiv-
ing cART.14 According to the Italian NeuroAIDS study 
2000–2002 (IRINA), PML is the third most common cause 
of encephalopathy in HIV-infected patients, after Toxoplasma 
encephalitis and HIV encephalitis.15 
More recently, PML has become a growing concern 
in patients under immunosuppressive therapies and mAbs 
treatment (such as natalizumab).7 PML cases are also 
associated with organ transplantation, solid malignancies, 
sarcoidosis, autoimmune disorders, and congenital immune 
deficiencies, even though these populations represent less 
than 10% of all reported PML cases.15 Some cases of PML 
have been described in patients affected by idiopathic CD4+ 
lymphocytopenia.16
JCV structure and replication
The JC polyomavirus was the first polyomavirus to be dis-
covered and, similar to other members of the polyomavirus 
family, has a double-stranded circular DNA genome of 
approximately 5 kb in size, enclosed in an icosahedral cap-
sid.17 The JCV genome consists of three parts:  a hypervari-
able noncoding control region (NCCR), a clockwise early 
coding region, and an anticlockwise late coding region.18 The 
early JCV transcript is responsible for encoding the majority 
of regulatory proteins: large and small tumor antigen proteins 
(T-antigen and t-antigen, respectively). The T-antigen is the 
key viral regulatory protein and acts as a transcriptional fac-
tor to direct DNA replication and to drive expression of the 
late viral transcript.19,20
The late JCV transcript encodes the capsid viral protein 
VP1, VP2, VP3, and a small regulatory phosphoprotein called 
agnoprotein, accounting for 71 amino acids.20,21 The capsid 
proteins (resulting from an alternative splicing of the late 
transcript) are essential for viral particles’ formation.17 
Agnoprotein forms highly stable dimers and oligomers and 
plays an important role in viral DNA replication by enhancing 
T-antigen binding to the origin of replication.21 
The early and late genes are characterized by highly con-
served sequences, while NCCR is the most variable portion 
of the viral genome within a single viral population, as well 
as across different species and genera.17,19 For this reason, 
NCCR is considered to be the main determinant of viral 
tropism, and changes in the NCCR region are associated with 
an increase in viral transcription and replication in patients 
with PML.22 The NCCR acts as a bidirectional viral promoter, 
separating the viral genome into early (clockwise) and late 
(anticlockwise) genes and each NCCR form always contains 
the highly conserved origin of DNA replication (ori), one or 
more TATA boxes, T-antigen binding sites, multiple cellular 
transcription factor binding sites, a promoter, and an enhancer 
for transcription of early and late genes.17 
Alignments of JCV NCCR sequences from several dif-
ferent patients and tissues allowed the identification of six 
blocks of sequences, named from A to F.17,19 The original 
isolate of JCV, known as MAD-1, contained an enhancer 
element constituted by a 98 bp tandem repeat (A-C-E-A-C-
E-F) due to the duplication of the TATA box. Several NCCR 
variants containing tandem repeat-like structures have been 
isolated from tissue of PML patients and all of these NCCR 
variants are named “prototype” sequences.22 Later, a non-
pathogenic variant of the NCCR region was found in the 
kidney and urine of healthy subjects and this strain was named 
“archetype”. Archetype-associated NCCR was composed of 
a single A-C-E unit that contained the 23 bp B block and the 
66 bp D block resulting in an A-B-C-D-E-F NCCR region. 
Notably, insertion of the B and D block sequences in the 
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NCCR region disrupts the integrity of several transcriptional 
binding factor sites, including YB-1/Purα, Oct-6, and NF-1. 
In conclusion, JCV exists in at least two different forms: a 
neurotropic form with rearranged NCCR (prototype) and a 
nonpathogenic form (archetype).22
Figure 1 shows JCV viral cycle in target cells.
Mechanism of cell invasion
JCV first attaches to the cell surface via an interaction between 
the JCV capsid protein VP1 and the pentasaccharide NeuNAc-
α2,6-Gal-β1,4-GlcNAc-β1,3-Gal-β1,4-Glc (LSTc).23 Viral 
particles then bind to receptors containing either α 2,3- or α 
2,6-linked sialic acids.24 It has been shown that JCV can infect 
glial cells after binding the 2A form of the 5HT
2A
R,24 but the 
presence of this receptor seems to be sufficient but not neces-
sary, as evidenced by infecting cell types lacking 5HT
2A
R (such 
as human brain microvascular endothelial cells) with JCV.25,26 
As a consequence of viral interaction with target receptors, the 
virus enters into the cells by a clathrin-dependent endocytosis 
mechanism,27,28 as demonstrated by JCV infection inhibition 
by molecules able to block the clathrin-mediated pathway.28,29 
Following clathrin-dependent endocytosis, ligands and 
viruses are usually carried to early endosomes and then shunted 
to recycling endosomes or to a late-endosomal/lysosomal com-
partment.30,31 The proper trafficking of cargos is regulated by 
early endosome membrane domains32 and by different Rab-fam-
ily GTPases.33,34 Inside endosomal vesicles, viral particles are 
transported through the endoplasmic reticulum to the nucleus. 
The first step of viral replication is the induction of early 
gene transcription by JCV T-antigen. This step could repre-
sent a potential key target for blocking JCV reactivation. JCV 
exploits several pathways to maintain cells in an immature 
stem cell-like phenotype. Expression of T-antigen, as well 
as the JCV late protein, agnoprotein, can also inhibit the 
differentiation of glial cells into a mature form.35,36 T-antigen 
can also allow infected cells to evade apoptosis. Through 
its interactions with the IGF-1 receptor, T-antigen enhances 
mTOR signaling and antiapoptotic protein expression.37 
A strategy for arresting JCV replication could be represented 
by the induction of autophagy with the molecular chaperone 
regulator-3 (BAG3), facilitating T-antigen degradation.38 
Once JCV infects permissive cells, the viral genome is 
readily transcribed, due to several binding sites for cellular 
transcription factors. After encoding for capsid proteins, 
the transcribed viral DNA is encapsulated and virions are 
released in a lytic process with the host cell death.39
Early endosome
Late endosome
Cytoplasm
Endoplasmic reticulum
9
5
6
DNA
RNA
RNA
Nucleus
2
3
4
8
1
7
Figure 1 JC virus (JCV) life cycle in target cells.
Notes: 1) JCV adhesion to receptors in target cells. 2) JCV internalization through clathrin mediated endocytosis and transport to the early endosomes. 3) Transport 
to either recycling or late endosomes. 4) Virus transport in the endoplasmic reticulum up to the nucleus. 5) DNA replication in the nucleus. 6) Early gene transcription 
(regulatory genes). 7) Late gene transcription (structural genes). 8) Translation of the transcripts from either early or late genes. 9) Viral particles’ assembly and virus release 
from target cells with either lytic (oligodendrocytes) or nonlytic mechanisms (tubular epithelial cells).
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T-antigen proteins are able to sequester key cell-cycle reg-
ulators, such as p53 and Rb, “hijacking” cell cycle machinery 
into an S-phase like state to maintain active viral replication.40 
JCV T-antigen selectively binds to wild type p53, a potent 
inducer of G1-phase cell cycle arrest, apoptosis, and DNA 
repair.41 This protein complex also enhances the expression 
of IGF-1, the receptor of which is another T-antigen binding 
partner, to further stimulate cell growth.42  When JCV infects 
tubular epithelial cells in the kidney, it usually establishes a 
nonlytic cycle, characterized by persistent urinary shedding 
of viral particles.9 
JCV/HIV interaction
The high incidence of PML in HIV-positive patients seems 
to be due to several factors: 1) CD4+ T-cell loss, with impair-
ment of immune surveillance of the CNS,43 2) the activation 
of CD8+ CTL responses with destruction of infected oligo-
dendrocytes,39 and 3) the presence of HIV in the brain, which 
may directly or indirectly participate in the pathogenesis of 
PML.43 
In HIV-infected subjects with PML, NCCR is character-
ized by multiple duplications of the upstream Tat-responsive 
element (up-TAR), which is also constantly found at the 
5′-end of HIV-1 mRNAs. Up-TAR is involved in HIV Tat 
induction of the JCV late promoter.44 Considering that Tat 
can induce its own expression and translation, establishing 
a positive feedback, JCV viral expression and viral protein 
production can be massively induced in PML HIV-infected 
subjects, by Tat transactivation of JCV viral genome tran-
scription.45–47 Notably, Tat enhances the ability of Pur-α48 
to bind the up-TAR element in the JCV-NCCR region, thus 
synergistically activating transcription 49 and contributing to 
PML pathogenesis during HIV infection. Despite HIV and 
JCV infecting different cell types, Tat protein is secreted 
by HIV-infected cells, such as microglial cells, astrocytes, 
and monocytes, and can be internalized by JCV-infected 
oligodendrocytes,50 contributing to  the enhancement of viral 
replication and transcription.49 
Concerning the different HIV-1 clades and JCV interac-
tions, HIV-1 clade B-associated Tat protein was found to be 
more effective in activating JCV early and late gene tran-
scription in glial cells, than Tat from other clades, in vitro.50 
Immune deficiency and JCV reactivation: 
immune pathogenesis of PML
The PML pathogenesis is still not completely clarified, since 
the source of the primary infection, the site of viral latency, 
and the route by which JCV enters into the brain have not 
been exactly understood. However, the conditions facilitat-
ing JCV-induced PML onset are well known: 1) changes 
in the NCCR with enhancement of viral transcription and 
replication, 2) availability of transcription factors binding the 
rearranged NCCR, 3) immunodeficiency, and 4) individual 
genetic predisposition.
JCV infection is highly prevalent in the worldwide 
population and after primary infection, which usually occurs 
during childhood, the virus can establish a latent infection 
with lifelong persistence.39 Considering anti-JCV antibody 
titers, infection rate increases with age, ranging from 10% of 
children aged 1–5 years and 40%–60% of children aged 10 
years, up to 50% and 68% of adults aged 20–29 and 60–100 
years, respectively.51
JCV infection is restricted to kidney epithelial cells, 
tonsillar stromal cells, bone marrow-derived cell lineages, 
oligodendrocytes, and astrocytes.17 The virus seems to rep-
licate efficiently in kidneys and bone marrow-derived cells, 
establishing a low-level persistent or latent infection. In the 
CNS, the virus replicates vigorously in oligodendrocytes 
causing the appearance of demyelinating lesions.17 The 
immune system plays a critical role in clearing JCV, through 
the action of specific B, CD4, and CD8 T-cell responses.52 
Initial infection results in a subclinical viral disease 
and generally remains clinically silent, despite active virus 
replication in the kidneys with urinary JCV-shedding in a 
large number of individuals.17 Upper respiratory airway may 
represent a feasible JCV entry site in humans, since JCV-
DNA was detected in both stromal cells and lymphocytes of 
children’s and adults’ tonsils. Contrasting evidences showed 
the presence of both prototype and archetype JCV in tonsillar 
tissue,53,54 so it is difficult to define the JCV circulating form 
causing primary infection. Moreover, JCV can infect splenic 
and bone marrow mononuclear cells.55 Notably, bone marrow 
has been considered one of the most important latency and 
neurotropism acquiring  sites for JCV.56 Specifically, bone 
marrow B-lymphocytes and CD34+ hematopoietic precursor 
cells are susceptible to JCV infection and are supposed to be 
a viral reservoir involved in NCCR rearrangement and viral 
carriage to the brain, especially in those conditions in which 
CD34+ progenitors and B-cell precursors are increased in 
peripheral blood (natalizumab treatment).17,52 
Nevertheless, studies in hematopoietic stem cell trans-
plant recipients showed that JCV can reactivate from kidney 
tubular cells independently from bone marrow latency sites, 
as demonstrated by the persistent JCV-urinary shedding 
in these patients before and after hematopoietic stem cell 
transplantation.57
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Classical PML in AIDS
PML is an AIDS defining disease, occurring almost exclu-
sively in the context of severe immune depression consequent 
to HIV infection.58 In this setting, we define the disease as 
AIDS-associated classical PML. 
The majority of HIV patients who develop PML have a CD4 
cell count <200 cells/µL, although there are some reports of 
PML cases in HIV-infected subjects with higher CD4 cell count. 
The incidence of PML in HIV-infected subjects has decreased 
after the introduction of cART, but it remains a major concern 
because of the lack of an effective direct acting anti-JCV drug.58
PML lesions are histopathologically characterized by 
demyelination, astrocyte modifications, and oligodendroglial 
nuclei changes, while edema, lymphocyte infiltration, and 
blood -brain barrier (BBB) damage are usually absent.59,60 
In AIDS-presenter therapy-naïve HIV-infected subjects 
with PML, the only therapeutic intervention is cART initia-
tion, with the aim of controlling HIV replication and conse-
quently improving the host immune system.61 If PML occurs 
in a cART-treated patient, who is experiencing either viro-
logical or immunological failure, a therapeutic optimization 
(switch or intensification) should be considered in order to 
better control HIV replication and improve CD4 cell count. 62
PML-immune reconstitution 
inflammatory syndrome
The immune reconstitution after cART initiation has been 
associated with the paradoxical worsening or the unmask-
ing of an opportunistic infection, asymptomatic or clinically 
controlled before ART initiation. Immune reconstitution 
inflammatory syndrome (IRIS) represents an exuberant 
inflammatory response to a dead, dying, or viable pathogen 
from a persistent infection.60,63,64 
PML-IRIS manifests as a neurologic deterioration with 
evidences of CNS JCV infection after cART initiation.63 
PML-IRIS lesions are pathologically different from classi-
cal PML, being characterized by lymphocyte perivascular 
infiltrates, BBB damage with brain edema, and consequent 
mass effect, which are lacking in classical PML lesions. Inter-
estingly, PML-IRIS brain lesions are infiltrated by cytotoxic 
CD8+ T lymphocytes that recognize and kill JCV-infected 
oligodendrocytes, controlling JCV dissemination but caus-
ing oligodendrocyte cell death and demyelination.65 Neuro-
imaging of PML-IRIS lesions is characterized by contrast 
enhancement as well as mass effect and interstitial edema.60
Considering the lack of an effective anti-JCV treatment, 
PML-IRIS therapy is essentially based on corticosteroids admin-
istration, with the aim of reducing brain inflammation. However, 
a case series of 54 patients with AIDS-associated PML-IRIS 
treated with corticosteroids showed contrasting results.66
PML diagnosis
PML clinical manifestations are heterogeneous and reflect 
the brain areas affected by the lesions. Most common clinical 
findings are motor weakness, gait abnormalities, speech and 
language disturbances, incoordination, visual field deficit 
(due to involvement of the optic radiations, whereas the optic 
nerve is usually spared). Less common clinical findings are 
sensory impairment, seizures, headache, and diplopia.59 
Definitive PML diagnosis relies on the presence of the clas-
sic histopathologic triad: demyelination, bizarre astrocytes, and 
enlarged oligodendroglial nuclei in the brain lesion biopsies, 
associated with the demonstration of the presence of JCV by 
either electron microscopy/immunohistochemistry or tissue 
polymerase chain reaction (PCR) positivity. The presence of 
the classic triad without evidence of JCV CNS infection by 
microscopy or molecular biology makes the diagnosis probable, 
whereas evidence of JCV through electron microscopy/immu-
nohistochemistry or tissue PCR without evidence of the typical 
histopathologic brain lesions makes the diagnosis possible.59,60 
Considering the difficulties in obtaining CNS biopsies, 
the diagnosis of PML can be achieved on the basis of clini-
cal features, neuroimaging, and cerebrospinal fluid (CSF) 
molecular biology testing. Notably, the presence of consistent 
clinical signs and symptoms, with positive neuroimaging 
findings and CSF JCV detection by PCR, make the PML 
diagnosis definite. The CSF JCV-PCR positivity in addition to 
either consistent clinical features or radiological alterations, 
suggest a diagnosis of probable PML, while the CSF JCV-
PCR positivity alone or merely the presence of clinical and 
neuroradiological findings consistent with PML, makes PML 
diagnosis possible. PML should be excluded when either 
compatible clinical features or compatible neuroimaging is 
associated with negative JCV-PCR in CSF.59
Beyond the classical diagnostic tools, several new diag-
nostic approaches have been evaluated for PML diagnosis 
in AIDS patients. 
CSF PCR viral load associated with NCCR sequencing 
is a useful tool  for the diagnostic and prognostic evalua-
tion of HIV-infected subjects affected by PML.67 JCV-DNA 
detection and quantification in plasma have been evaluated 
for their predictive value in terms of PML onset, but lacked 
a definitive demonstration of any association.68 
NCCR deep sequencing is providing new insights into 
PML pathogenesis. It has been shown that archetype-like 
JCV is the predominant population in urine, in the absence of 
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minor variants. In CSF, JCV viral population is a mixture of 
several recombined forms, contributing to the constitution 
of a “quasispecies”. Moreover, viral quasispecies in CSF 
and blood seem to be strongly correlated in PML-affected 
patients, suggesting the main role of the hematogenous route 
in JCV dissemination from latency sites to the CNS.69,70
JCV serology has been a very useful tool in identifying 
JCV-infected multiple sclerosis patients, candidates for natali-
zumab treatment, and those at higher risk of JCV reactivation. 
However, JCV serologic screening alone does not identify all 
JCV-infected individuals, given the presence of seronegative 
subjects with PCR detectable JCV-DNA in blood or urine.71 
Accordingly, JCV-DNA urine testing is complementary to 
anti-JCV serostatus assessment in identifying patients at risk 
for PML (at least in natalizumab-treated patients).72 Further-
more, no evidence of correlations between serum anti-JCV-
specific IgG titers and PML onset was found.68 
JCV urinary shedding may also occur in healthy subjects73 
and JCV viral load in urine seems to be unchanged when 
comparing HIV-positive subjects with and without PML.74 A 
new diagnostic tool could be represented by JCV-associated 
microRNAs’ detection and quantification in human blood, 
urine, and CSF.75 Specifically, Jcv-miR-J1 can be used in 
order to identify the presence of a latent JCV infection, with 
a higher detection rate than JCV-specific serology.76 Further 
studies are needed to understand the predictive value of 
microRNAs for PML diagnosis.
Magnetic resonance imaging (MRI) represents a para-
mount noninvasive tool for PML diagnosis. Classically, PML 
lesions appear as single or multiple hyperintense areas in 
T2-weighted images, slightly hypointense in T1-weighted 
images, mainly subcortical, involving the white matter 
(although the gray matter can be involved), without mass 
effect. Typically, lesions do not appear enhanced after contrast 
administration. Diffusion-weighted images with apparent 
diffusion coefficient maps, diffusion tensor imaging (which 
analyzes the degree of fractional anisotropy), white matter 
magnetic resonance spectroscopy, and magnetization transfer 
imaging represent magnetic resonance techniques which can 
improve differential diagnosis and prognostic assessment 
of PML.77 PML-IRIS-associated lesions may show contrast 
enhancement on MRI examination, because of inflammation 
and BBB disruption. Brain edema, swelling, and mass effect 
can also be found with MRI in this setting.68
PML therapy
The introduction of cART improved the prognosis of patients 
with AIDS-related PML.61 In particular, protease inhibitor 
based ART seems to be associated with better survival, 
regardless of the CNS penetration score.62 
Several drugs targeting serotonin receptors and inhibiting 
viral entry have shown an antiviral effect in vitro, such as 
chlorpromazine, citalopram, risperidone, ziprasidone, and 
mirtazapine. Risperidone’s efficacy was challenged by nega-
tive results in inhibiting JCV infection of glial cells in vitro.78 
Furthermore, a definitive demonstration of the in vivo efficacy 
of these drugs is still lacking and for some of them is weakly 
supported by some case reports.79 Retro-2cycl and brefeldin A 
are able to interfere with viral replication by inhibiting retro-
grade transport of JCV to the endoplasmic reticulum in vitro, 
while no in vivo data are available so far. Nucleoside analog 
cytarabine; nucleotide analogs cidofovir and brincidofovir; 
small molecules like ganciclovir, topotecan, and leflunomide; 
the antimalarial drug mefloquine; Poly (ADP-ribose) poly-
merase inhibitors; the protein kinase inhibitor imatinib; and 
siRNA Ag122 (which targets JCV agnoprotein) have shown 
anti-JCV activity in vitro, by inhibiting viral DNA replication. 
Cytarabine, cidofovir, and brincidofovir activity also affects 
host cell polymerase causing toxicity, which limits their utili-
zation in clinical settings. The in vivo efficacy of ganciclovir 
and leflunomide was supported by some case reports. siRNA 
Ag122 seemed to be effective in inhibiting JCV replication in 
a PML mouse model, while no human data are available so 
far. 7 A recent paper evidenced the potential antiviral effect of 
the antimalarial drug artesunate, which showed the ability to 
inhibit JCV viral cycle in vitro in the monkey kidney cell line 
COS-7. In vitro, artesunate’s half maximal effective concentra-
tion can be achieved in human plasma without toxic effects 
and its active metabolite dihydroartemisinin accumulates in 
the CNS. Clinical studies are needed to demonstrate the in 
vivo antiviral efficacy of artesunate.79
Furthermore, several drugs have been tested in clinical 
studies, for their anti-JCV potential activity during AIDS-
related PML. In one Phase II clinical trial, HIV-positive 
patients with PML were randomly assigned to three differ-
ent arms: treatment with cART alone, cART in combination 
with either intravenous or intrathecal cytarabine. The overall 
survival in the three arms was similar and cytarabine did not 
improve the prognosis of HIV-infected patients with PML.7 
A pilot study and analysis of data from one prospective 
study and five cohort studies on cidofovir administration to 
HIV-positive patients with PML did not show any benefit in 
reducing mortality and residual disability.7 A Phase II clinical 
uncontrolled trial failed to demonstrate topotecan’s efficacy 
in HIV-related PML, because of the small number of enrolled 
subjects and the high rate of adverse events directly related 
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to this drug.7 Retrospective analyses of observational studies 
demonstrated the inefficacy of IFN-alpha, while for IFN-beta 
only anecdotal reports are available. Both IFN-alpha and -beta 
are no longer considered as potential treatments for PML. 
For IL-2 and IL-7, only anecdotal data are available.7,58 More 
recently, treatment of AIDS-related PML with mefloquine 
and mirtazapine has been described in several case reports, 
with contrasting outcomes.80–82 Limited evidences of meflo-
quine efficacy in non-AIDS-related PML and AIDS PML-
IRIS have been described. In both cases, the demonstration 
of mefloquine efficacy was not definitive, considering that in 
non-AIDS-related PML the immune suppressive condition 
is often removed (drug suspension and plasmapheresis),83 
while in AIDS PML-IRIS the immune reconstitution due 
to cART could play a major role.84 Larger studies did not 
confirm the efficacy of mefloquine for PML treatment.85 
The CCR5 blocker maraviroc was associated with clinical 
improvement in three non-HIV subjects with PML (patients 
had immunological disorders: two patients had sarcoidosis, 
the third had idiopathic CD4+ lymphocytopenia). Maraviroc 
can act indirectly, by positively influencing CD4+ T lympho-
cyte reconstitution and modulating immune activation, and 
directly by interfering with the levels of nuclear transcription 
factor which enhance JCV replication in oligodendrocytes. 
Maraviroc seems to increase the survival of HIV-positive and 
natalizumab-treated patients affected by PML-IRIS. Further 
studies are needed to assess maraviroc’s efficacy in the treat-
ment of HIV-associated classical PML.86
Table 1 Potential candidates for PML treatment with anti-JCV activity
Drug name Mechanism of action Preclinical studies Clinical studies
Chlopromazine JCV cell entry inhibition In vitro studies showing inhibition of JCV infection /
Citalopram In vitro studies showing inhibition of JCV infection /
Risperidone In vitro studies on glial cells did not show inhibition of 
JCV infection
Case reports claiming efficacy
Ziprasidone / Case reports claiming efficacy
Mirtazapine In vitro studies showing inhibition of JCV infection Case reports claiming efficacy
Retro-2cycl Retrograde transport 
inhibition
In vitro studies showing inhibition of JCV infection /
Brefeldin A In vitro studies showing inhibition of JCV infection /
Cidofovir DNA replication inhibition In vitro studies showing inhibition of BKV infection Clinical studies: no evidence of efficacy
Brincidofovir In vitro studies showing inhibition of JCV infection Case reports claiming efficacy
Cytarabine In vitro studies showing inhibition of JCV infection Clinical study: no evidence of efficacy
Gancyclovir In vitro studies showing inhibition of CMV and JCV 
infection
Case reports claiming efficacy
Leflunomide In vitro studies showing inhibition of BKV and JCV 
infection
Case reports claiming efficacy
Topotecan In vitro studies showing inhibition of JCV infection Clinical study: no evidence of efficacy
Mefloquine Antimalarial drugs: 
mechanism unknown
In vitro studies showing inhibition of JCV infection Clinical study: no evidence of efficacy
Artesunate In vitro studies showing inhibition of JCV infection
3-aminobenzamide 
(3-AB)
PARP inhibitors In vitro studies showing inhibition of JCV infection /
Imatinib Protein kinase inhibitor In vitro studies showing inhibition of JCV infection /
Ag122 siRNA against JCV 
agnoprotein 
In vitro studies showing inhibition of JCV infection /
IFN-alpha Induction of antiviral 
immunity
/ Clinical study: no evidence of efficacy
IFN-beta / Case reports claiming efficacy
IL-2 Immune-modulation / Case reports claiming efficacy
IL-7 / Case reports claiming efficacy
Maraviroc / Case reports claiming efficacy
Recombinant 
human anti-JCV 
VP-1 monoclonal 
antibodies 
Passive immunization In vitro studies showing inhibition of JCV infection /
JCV-specific cytotoxic 
T lymphocyte  
/ Case report claiming efficacy
IL-7 + JCV VP1 
Vaccine 
Active immunization / Case reports claiming efficacy
JCV oral vaccine / /
Note: “/”, no data.
Abbreviations: JCV, JC virus; PML, progressive multifocal leukoencephalopathy; IFN, interferon; IL, interleukin; VP, viral protein; PARP, Poly (ADP-ribose) polymerase; 
BKV, BK virus; CMV, cytomegalovirus.
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Passive immunization strategies (recombinant JCV 
VP1-specific mAbs and JCV-specific cytotoxic T lympho-
cyte) and active immunization approaches  (by using VP1 
epitopes with and without IL-7 boosting) are currently 
under development.7 Recently, a fluorescent JCV viral 
construct was obtained in laboratory, allowing for the pos-
sibility of rapid screening of several molecules with the 
capacity of inhibiting JCV replication in cell cultures.87 
A new and promising approach for PML treatment could 
be the gene editing procedures based on the clustered 
regularly interspaced short palindromic repeats (CRISPR)/
CAS9 technology.88,89 Table 1 summarizes molecules with 
potential anti-PML activity with in vitro or in vivo efficacy 
in inhibiting JCV replication.  
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